4Fraco A,Col N,Chlebowski N T.Discordancer in estrogen(ER) and progestin receptor(PR) status between primary metastatic breast can- cer, a meta-analysis[J].J Clin Oneol, 2004,22 (14s) : 539-540.
5Lindstrom L S,Karlsson E,Wiking U M,et al.Clinically used breast cancer markers such as estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 are unstable throughout tu- mor progression[J].J Clin Oncol, 2012,30(21 ) : 2601-2608.
4Hussein MR, Abd - Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors,progesterone receptors and c - erbB2 oncogene protein expression in ductal carcinomas of the breast[ J ]. Cell Biol Int,2008,32(6) :698 -707.
5Yamauchi H,Stearns V, Hayes DF, et al. The role of c - erbB2 as a predictive factor in breast cancer [ J ]. Breast Cancer,2001,8 (3) : 171 - 183.
6Brown M,Tsodikov A,Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer: the California Cancer Registry, 1999 - 2004 [ J ]. Cancer, 2008, 112 (4) :737 -747.
7Anim JT,John B Abdulsathar S SA,et al Relationship between the expression of various markers and prognostic factors in breast cancer[J]. Acta Histochem,2005,107(2) :87 -93.
8McGuire WL,Clack GM. Prognostic factor and treatment decision in axillary - node - negative breast cancer[ J]. N Engl J Med, 1992, 326(26) :1756 - 1759.
2Yao ZX, Lu LJ, Wang RJ, et al. Discordance and clinical signifi- cance of ER, PR, and HER2 status between primary breast can- cer and synchronous axillary lymph node metastasis[J]. Med On- eol,2014,31 ( 1 ):798. DOI:10.1007/s12032-013-0798-y.
3Ba JL, Liu CG, Jin F. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis[J]. Asian Pac J Cancer Prey,2014,15 (21):9233-9239. DOI:lO.7314/APJCP.2014. 15.21.9233.
4Sun L, Yu DH, Sun SY, et al. Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast can- cers[J]. Cell Bioehem Biophys,2014,68 (3):511-516. DOI:IO.IO07/ s12013-013-9729-y.
5Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen re- ceptor status, progesterone receptor status, and HER2 status be- tween primary breast cancer and metastasis[J]. Oncologist,2013,18 (6):667-674. DOI: 10.1634/theoncologist.2012-0350.
6Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors[J]. J Clin Oncol,2012, 30(6):593-599. DOI: 10.1200/JCO.2010.33.8889.
7Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer[J]. J Clin Oncol,2012,30(6):587-592. DOI:10.1200/JCO. 2010.33.5232.
8Thompson AM, Jordan LB, Quinlan P, et al. Prospective compari- son of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS)[J]. Breast Cancer Res,2010,12(6):R92. DOI:10.1186focr2771.
9Aitken SJ, Thomas JS, Langdon SP, et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast can- cer and paired nodal metastases[J]. Ann Oncol,2010,21 (6):1254- 1261. DOI: lO.1093/annonc/mdp427.
10Falck AK, Fern M, Bendahl PO, et al. Does analysis of biomark- ers in tumor cells in lymph node metastases give additional prog- nostic information in primary breast cancer[J]? World J Surg, 2010, 34(7):1434-1441. DOI:I 0.1007/s00268-010-0499-z.
